Description:
Alecinix (Alectinib) is a kinase inhibitor used to treat adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who have stopped responding to Crizotinib or can’t take it. Alecinix (Alectinib) is used as a first-line treatment for adults with advanced non-small cell lung cancer that is positive for anaplastic lymphoma kinase (ALK) (NSCLC)
Dosing & Administration:
- Alectinib should be taken by mouth twice a day at a dose of 600 mg. Give Alectinib until the disease worsens or the side effects are too much.
- For people with severe liver damage (Child-Pugh C), the recommended dose of Alectiib is 450 mg twice a day.
- It is best to take Alectinib with food. Don’t open the capsule or try to get the contents out. If you miss a dose of Alectinib or throw up after taking an amount, take the next dose at the time you were supposed to.
Side Effects:
- Hepatotoxicity
- Interstitial Lung Disease (ILD)/Pneumonitis
- Renal Impairment • Bradycardia
- Severe Myalgia and Creatine Phosphokinase (CPK) Elevation
- Embryo-Foetal Toxicity
Breastfeeding Warnings:
Since this drug is bound to plasma proteins more than 99 percent of the time, there is probably not much of it in breast milk. However, its half-life is 33 hours so that it may build up in the baby. It’s not a good idea to use. They do not know what gets into human milk.
Excreted into animal milk: Data not available
Comment: We don’t know how it will affect the baby and how much milk it will make.
-It is not a good idea to breastfeed during therapy or for a week.
Storage:
Keep away from light and in a cool, dry place. Keep out of children’s reach.
Reviews
There are no reviews yet.